Goldman Sachs Group Inc Bluebird Bio, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BLUE
# of Institutions
151Shares Held
63.4MCall Options Held
264KPut Options Held
428K-
Black Rock Inc. New York, NY15.4MShares$6.49 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.5MShares$4.4 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA4.68MShares$1.97 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V84.67MShares$1.96 Million0.02% of portfolio
-
State Street Corp Boston, MA3.84MShares$1.61 Million0.0% of portfolio
About bluebird bio, Inc.
- Ticker BLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,121,800
- Market Cap $32.4M
- Description
- bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...